Mitophagy
A selective form of autophagy in which the cell recognizes and removes specifically damaged, dysfunctional mitochondria — a mitochondrial quality-control mechanism whose efficiency declines with age and is studied in the context of neurodegenerative disease.
Number of studies
2
Safety
High
Time to effects
Not applicable — mitophagy is a biological process studied experimentally, not an intervention with a measurable time to effect in humans.
Who it's for
Table of contents
TL;DR
A selective form of autophagy in which the cell recognizes and removes specifically damaged, dysfunctional mitochondria — a mitochondrial quality-control mechanism whose efficiency declines with age and is studied in the context of neurodegenerative disease.
- →Removes damaged, dysfunctional mitochondria, theoretically limiting overproduction of reactive oxygen species and mitochondrial DNA leakage
- →May play a protective role in the context of neurodegenerative diseases, including Parkinson's disease (data mainly from cell and genetic models)
- →Represents one of the key mitochondrial quality-control mechanisms studied as a potential target for future anti-aging interventions
| Process type | Selective form of autophagy targeting exclusively damaged mitochondria |
|---|---|
| Research level | Early-stage — mechanism well characterized in cell and animal models, measurement in humans still experimental |
| Key pathway | PINK1 and Parkin (PRKN) proteins tag damaged mitochondria with ubiquitin |
| Clinical link | PINK1/PRKN mutations are one of the known genetic causes of familial Parkinson's disease |
| Relation to autophagy | A subtype of autophagy specialized in mitochondria, not identical to general autophagy |
| Human measurement methods | Mostly experimental (e.g., blood p-S65-Ub phospho-ubiquitin assay), no standard clinical test |
| Status | Subject of active basic research, not a standardized biomarker |
Understand
Overview
Mitophagy is a selective form of autophagy in which the cell specifically recognizes damaged or dysfunctional mitochondria and directs them to the lysosome for degradation, rather than breaking down random cytoplasmic components. This is an important distinction: general autophagy (covered in a separate entry) targets a broad range of damaged proteins and organelles, whereas mitophagy is its specialized subtype, focused exclusively on mitochondria — the cell's 'power plants,' which accumulate mitochondrial DNA damage and lose energy-production efficiency with age.
Interest in mitophagy in the context of aging stems from the fact that mitochondrial dysfunction is one of the commonly cited hallmarks of cellular aging, and its efficient removal is theorized to limit the accumulation of damaged organelles, mitochondrial DNA leakage, and overproduction of reactive oxygen species. The PINK1/Parkin pathway, the main mechanism for recognizing damaged mitochondria, has gained additional clinical significance because mutations in the PINK1 and PRKN (Parkin) genes are one of the known genetic causes of familial Parkinson's disease — making mitophagy an important area of neurodegeneration research, not just general aging biology.
Who can realistically benefit from this? Primarily people interested in mitochondrial aging biology as scientific context — not as a ready-made, measurable intervention. It's worth being skeptical of any commercial tests or supplements marketed as tools that 'measure' or 'activate' mitophagy — direct measurement of this process in a living person remains largely experimental and is not available as a standardized clinical test.
Mechanism of action
The process begins when the mitochondrial membrane potential drops due to damage — a signal that a given mitochondrion has stopped efficiently producing energy. In a healthy mitochondrion, the protein PINK1 is continuously imported into the organelle and degraded, but in a damaged mitochondrion this import is blocked, causing PINK1 to accumulate on its outer membrane. Accumulated PINK1 phosphorylates ubiquitin (at serine 65) and recruits and activates the enzyme Parkin (the product of the PRKN gene), which coats the surface of the damaged mitochondrion with additional ubiquitin chains — this phospho-ubiquitin pattern (p-S65-Ub) is the molecular 'remove me' signal, also used as an experimental blood biomarker of mitophagy. The tagged mitochondrion is then recognized by autophagy receptors (besides the PINK1/Parkin pathway, proteins such as BNIP3, NIX/BNIP3L, and FUNDC1 also participate), surrounded by a double membrane forming a mitophagosome, and transported to the lysosome, where it is fully degraded by the same lysosomal machinery that handles general autophagy.
Mitophagy acts as a 'last line of defense' in the hierarchy of mitochondrial quality control — it removes the entire organelle when damage is too extensive to repair. It is complemented by the mitochondrial unfolded protein response (UPRmt, covered in a separate entry), which acts at an earlier stage, attempting to restore proper protein folding inside a still-functioning mitochondrion before removal of the whole organelle becomes necessary.
Damage recognition
A drop in mitochondrial membrane potential blocks PINK1 degradation, causing it to accumulate on the damaged organelle's surface.
Ubiquitin tagging
PINK1 phosphorylates ubiquitin and recruits Parkin, coating the damaged mitochondrion with ubiquitin chains as a removal signal.
Mitophagosome formation
A double membrane surrounds the tagged mitochondrion, forming a structure analogous to an autophagosome but specific to this organelle.
Lysosomal degradation
The mitophagosome fuses with the lysosome, where enzymes break the mitochondrion down into simple, recyclable components.
Evidence: early-stage — based on 2 studies in this database.
Benefits
Common myths
MythMitophagy and autophagy are exactly the same thing.
FactMitophagy is a subtype of autophagy specialized in the selective removal of damaged mitochondria — general autophagy covers a much broader range of cellular components, including other organelles and damaged proteins.
MythA commercially available blood test can precisely measure your 'mitophagy level.'
FactMethods for measuring mitophagy in humans, such as the p-S65-Ub phospho-ubiquitin assay, remain at the research stage and are not standardized clinical tools available in routine diagnostics.
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
Mitophagy is a subtype of autophagy targeting exclusively damaged mitochondria — it uses the same lysosomal machinery but requires an additional step of selectively recognizing the damaged organelle, e.g., via the PINK1/Parkin pathway.
Direct measurement of mitophagy in a living person remains largely experimental — tests such as blood p-S65-Ub phospho-ubiquitin measurement have shown promising results in research studies but are not available as a standard clinical test.
Mutations in the PINK1 and PRKN genes, key elements of the damaged-mitochondria recognition pathway, are one of the known genetic causes of familial Parkinson's disease, making mitophagy an important area of neurodegeneration research.
Studies in animal and cell models suggest increased mitophagy activation during fasting and caloric restriction, similar to general autophagy, but there is much less direct clinical evidence in humans.
What to combine with
Good combinations
Autophagy — Mitophagy uses the same lysosomal machinery as general autophagy but requires an additional step of selectively recognizing the damaged mitochondrion
UPRmt — UPRmt refolds misfolded proteins inside the mitochondrion, while mitophagy removes the entire organelle when damage is too extensive to repair
Safety
Side effects & contraindications
Possible side effects
Contraindications
No significant contraindications at typical doses.
Is it worth taking?
Who it's for
- People interested in the biology of mitochondrial aging
- People who want to understand the difference between general autophagy and mitochondria-specific processes
Not for
- No significant contraindications at typical doses.
Evidence
Worth knowing
Key proteins of the PINK1/Parkin pathway have been linked to the familial form of Parkinson's disease, making mitophagy an important area of neurodegeneration research, not just aging biology.
Besides the PINK1/Parkin pathway, receptors such as BNIP3, NIX/BNIP3L, and FUNDC1 also participate in recognizing damaged mitochondria.
Studies
Mitophagy in human health, ageing and disease
Moderate evidencePicca A, Faitg J, Auwerx J, et al. · Nature Metabolism · 2023
A comprehensive review of mitophagy mechanisms and their significance for health, aging, and age-related diseases, summarizing the current state of basic-science knowledge and clinical implications of impaired mitophagy.
View studySensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples
Early-stage evidenceFiesel FC, et al. · Autophagy · 2021
Development of a sensitive ELISA assay detecting phospho-ubiquitin (p-S65-Ub) — a marker of PINK1/Parkin pathway activity — in human cells, brain tissue, and blood plasma, able to distinguish PINK1 mutation carriers from healthy individuals; an early-stage research tool, not a standard clinical test.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
121 publications on this site
Medical review
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
174 publications on this site
Related entries
4.3Autophagy
An intracellular 'housekeeping' process that clears out damaged proteins and organelles, whose discovery earned a Nobel Prize — one of the key mechanisms studied in the context of slowing aging.
4.0UPRmt
The mitochondrial unfolded protein response (UPRmt) is an intracellular repair program that protects mitochondria from stress — linked to lifespan extension in model organisms, though the relationship turned out to be more complex than initially thought.
4.2Biological Age Clocks
An umbrella term covering very different methods for estimating the 'true' pace at which an organism is aging — from well-validated second-generation epigenetic clocks to far less proven commercial tests based on glycans or the microbiome. Not all of them carry a comparable level of evidence.
4.2TFEB
The transcription factor TFEB acts as a master on-off switch for autophagy and the production of new lysosomes in the cell — one of the best-characterized molecular nodes linking these two processes, studied as a potential target for interventions in aging.
4.2NAD+ Recycling
The level of NAD+ in the body isn't just about how much of the coenzyme a cell makes from scratch — it's mainly about how efficiently it reclaims NAD+ from the byproducts of its own breakdown, a process called the salvage pathway, whose efficiency declines with age regardless of how much precursor is supplied through diet or supplements.
4.1Proteostasis
A cell's ability to maintain balance between protein production, correct folding, and degradation — a network of mechanisms whose capacity declines with age and is studied as one of the fundamental pillars of cellular aging.
3.9Lysosomal Health
Lysosomes — the cell's 'recycling centers' — accumulate unprocessed waste and lose capacity with age, a pattern increasingly described as one of the fundamental, shared denominators of cellular aging and a potential target for future interventions.
Related articles
Badania naukoweWhat we now know about NMN and longevity — a review of human studies
NMN, a precursor of NAD+, has for years been one of the most hotly debated supplements in the biohacking community. We look at what the latest clinical trials in humans show, as distinct from earlier studies in mice.
August 11, 2026
Badania naukoweLongevity Vitamins: Which Supplements Actually Have Real Scientific Evidence Behind Them
Every supplement shelf promises a longer life in every capsule, but the hard data from large clinical trials tells a far more measured story. We go through which vitamins genuinely extend healthy lifespan in people with a real deficiency, and which — despite their popularity — have no supporting evidence at all, or worse, evidence of no benefit.
August 20, 2026
PoradnikiNMN vs NAD+ vs Resveratrol — What Actually Extends Life?
Three of the biggest names in longevity, one shared hypothesis, and a very different level of evidence in humans for each. An honest comparison of mechanism, clinical trial quality, and monthly cost — with no marketing rounding up.
August 20, 2026
PoradnikiVitamin D3 and Longevity — Does a Deficiency Shorten Your Life?
Low vitamin D levels correlate with higher mortality across dozens of observational studies, yet the massive randomized VITAL trial found no evidence that supplementation extends life in people without a deficiency. We break down this apparent contradiction piece by piece.
August 20, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.